TISIDB

Summary
Symbol	NPR3
Name	natriuretic peptide receptor 3
Aliases	FLJ14054; guanylate cyclase C; NPRC; ANPRC; C5orf23; chromosome 5 open reading frame 23; atrionatriuretic pe ......
Chromosomal Location	5p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Membrane; Single-pass type I membrane protein.
Domain	PF01094 Receptor family ligand binding region
Function	Receptor for the natriuretic peptide hormones, binding with similar affinities atrial natriuretic peptide NPPA/ANP, brain natriuretic peptide NPPB/BNP, and C-type natriuretic peptide NPPC/CNP. May function as a clearance receptor for NPPA, NPPB and NPPC, regulating their local concentrations and effects. May regulate diuresis, blood pressure and skeletal development. Does not have guanylate cyclase activity.

> Gene Ontology [ TOP ]
Biological Process	GO:0001501 skeletal system development GO:0002158 osteoclast proliferation GO:0003013 circulatory system process GO:0003014 renal system process GO:0007187 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007188 adenylate cyclase-modulating G-protein coupled receptor signaling pathway GO:0007193 adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway GO:0007200 phospholipase C-activating G-protein coupled receptor signaling pathway GO:0007586 digestion GO:0007589 body fluid secretion GO:0008015 blood circulation GO:0008217 regulation of blood pressure GO:0019932 second-messenger-mediated signaling GO:0019933 cAMP-mediated signaling GO:0019935 cyclic-nucleotide-mediated signaling GO:0022600 digestive system process GO:0030157 pancreatic juice secretion GO:0032768 regulation of monooxygenase activity GO:0032770 positive regulation of monooxygenase activity GO:0032941 secretion by tissue GO:0033002 muscle cell proliferation GO:0033687 osteoblast proliferation GO:0033688 regulation of osteoblast proliferation GO:0035809 regulation of urine volume GO:0035810 positive regulation of urine volume GO:0048015 phosphatidylinositol-mediated signaling GO:0048017 inositol lipid-mediated signaling GO:0048659 smooth muscle cell proliferation GO:0048660 regulation of smooth muscle cell proliferation GO:0048662 negative regulation of smooth muscle cell proliferation GO:0050878 regulation of body fluid levels GO:0050999 regulation of nitric-oxide synthase activity GO:0051000 positive regulation of nitric-oxide synthase activity GO:0051341 regulation of oxidoreductase activity GO:0051353 positive regulation of oxidoreductase activity GO:0070661 leukocyte proliferation
Molecular Function	GO:0001653 peptide receptor activity GO:0008528 G-protein coupled peptide receptor activity GO:0016941 natriuretic peptide receptor activity GO:0017046 peptide hormone binding GO:0033218 amide binding GO:0042277 peptide binding GO:0042562 hormone binding
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	-

Summary
Symbol	NPR3
Name	natriuretic peptide receptor 3
Aliases	FLJ14054; guanylate cyclase C; NPRC; ANPRC; C5orf23; chromosome 5 open reading frame 23; atrionatriuretic pe ......
Chromosomal Location	5p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between NPR3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	NPR3
Name	natriuretic peptide receptor 3
Aliases	FLJ14054; guanylate cyclase C; NPRC; ANPRC; C5orf23; chromosome 5 open reading frame 23; atrionatriuretic pe ......
Chromosomal Location	5p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of NPR3 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	NPR3
Name	natriuretic peptide receptor 3
Aliases	FLJ14054; guanylate cyclase C; NPRC; ANPRC; C5orf23; chromosome 5 open reading frame 23; atrionatriuretic pe ......
Chromosomal Location	5p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of NPR3 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.128	0.647
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.492	0.324
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.143	0.749
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	1.172	0.025
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	1.419	0.279
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.853	0.564
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.348	0.61
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.118	0.909
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.634	0.564
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.624	0.283
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	3.284	0.0887
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.599	0.0122

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of NPR3 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	0	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	7.4	6.8	0.6	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	7.4	8.5	-1.1	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	0	11.1	0.36
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	20	0	20	0.357
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	NPR3
Name	natriuretic peptide receptor 3
Aliases	FLJ14054; guanylate cyclase C; NPRC; ANPRC; C5orf23; chromosome 5 open reading frame 23; atrionatriuretic pe ......
Chromosomal Location	5p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NPR3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	NPR3
Name	natriuretic peptide receptor 3
Aliases	FLJ14054; guanylate cyclase C; NPRC; ANPRC; C5orf23; chromosome 5 open reading frame 23; atrionatriuretic pe ......
Chromosomal Location	5p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NPR3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NPR3. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	NPR3
Name	natriuretic peptide receptor 3
Aliases	FLJ14054; guanylate cyclase C; NPRC; ANPRC; C5orf23; chromosome 5 open reading frame 23; atrionatriuretic pe ......
Chromosomal Location	5p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NPR3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	NPR3
Name	natriuretic peptide receptor 3
Aliases	FLJ14054; guanylate cyclase C; NPRC; ANPRC; C5orf23; chromosome 5 open reading frame 23; atrionatriuretic pe ......
Chromosomal Location	5p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of NPR3 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	NPR3
Name	natriuretic peptide receptor 3
Aliases	FLJ14054; guanylate cyclase C; NPRC; ANPRC; C5orf23; chromosome 5 open reading frame 23; atrionatriuretic pe ......
Chromosomal Location	5p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between NPR3 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	NPR3
Name	natriuretic peptide receptor 3
Aliases	FLJ14054; guanylate cyclase C; NPRC; ANPRC; C5orf23; chromosome 5 open reading frame 23; atrionatriuretic pe ......
Chromosomal Location	5p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting NPR3 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting NPR3.

ID	Name	Drug Type	Targets	#Targets
DB04899	Nesiritide	Biotech	NPR1, NPR2, NPR3	3

Browse NPR3